Peritoneal Carcinomatosis: Causes, Symptoms, Diagnosis and Treatment Options in India

Peritoneal carcinomatosis is the spread of cancer cells to the peritoneum — the thin, delicate membrane that lines the inside of the abdominal cavity and covers many abdominal organs including parts of the stomach, intestines and liver.

When cancer cells reach this membrane, they may attach to its surface and develop into small or large tumour deposits. These deposits can appear in different parts of the abdomen and may affect the normal movement of intestines or circulation of fluid inside the cavity. The term is often used when cancer from another organ has spread to the peritoneum.

Peritoneal carcinomatosis generally refers to cancer that has spread to the peritoneum from another primary site such as the colon, stomach, ovary or appendix. Primary peritoneal cancer begins in the cells of the peritoneum itself and is a distinct diagnosis with similarities to epithelial ovarian and fallopian tube cancers.

The distinction matters because the original site and tumour biology influence treatment selection. A specialist team will normally review the original pathology report, imaging and biopsy findings before recommending treatment.

Colorectal cancer may spread to the peritoneum through direct extension, lymphatic spread or by releasing cells into the abdominal cavity. Peritoneal metastases may develop at the time of original diagnosis or after treatment. Selected patients may be assessed for cytoreductive surgery.

Ovarian cancer frequently spreads within the abdominal cavity. The peritoneum, omentum and organ surfaces may become involved. In selected patients, cytoreductive surgery and HIPEC may form part of treatment planning under specific clinical circumstances.

Gastric cancer can spread to the peritoneum. Some appendiceal tumours produce mucus that accumulates in the abdomen — a condition known as pseudomyxoma peritonei. Selected patients with appendiceal malignancies may be assessed for cytoreductive surgery combined with HIPEC. Peritoneal involvement may also occur in endometrial, gallbladder, bile duct, pancreatic, small bowel and other abdominal cancers.

Symptoms can vary considerably. Some patients have very few symptoms in early stages, while others develop noticeable abdominal problems.

Diagnosis requires confirming the presence of cancer, understanding its origin, determining extent and assessing whether treatment can be directed at the peritoneal deposits. Patients seeking a specialist opinion in India should arrange a review of their previous scans and pathology before travelling.

The PCI is a scoring system that describes the extent of tumour deposits inside the abdominal cavity. The abdomen and pelvis are divided into 13 regions, each receiving a score based on the largest tumour deposit found. The combined score ranges from 0 to 39. A higher score generally indicates greater disease burden.

PCI helps the specialist team assess disease distribution, whether complete cytoreductive surgery may be achievable, and the potential complexity of surgery. However, PCI should not be interpreted in isolation. Location of deposits, small bowel involvement, tumour biology and overall health all matter. There is no single PCI cut-off for every cancer. Indian expert consensus also emphasises considering both the total PCI and the score for each of the 13 regions.

Systemic chemotherapy uses medicines that travel through the bloodstream. It may be used before surgery (to assess tumour response), after surgery, when surgery is not appropriate, or to control disease and symptoms. The regimen depends on the primary cancer and molecular characteristics.

Targeted therapy acts on specific molecular features involved in cancer growth. For colorectal cancer, relevant biomarkers include RAS, BRAF and HER2 status. Some patients with mismatch repair-deficient or microsatellite instability-high colorectal cancer may benefit from immune checkpoint inhibitors. Testing and specialist assessment are essential — these are not universal treatments.

Cytoreductive surgery aims to remove visible tumour deposits from the peritoneal surfaces. It may involve peritonectomy, omentectomy, bowel resection and removal of other involved structures. The objective is complete or near-complete removal of visible disease. CRS is a major operation requiring careful patient selection and an experienced surgical team.

HIPEC (Hyperthermic Intraperitoneal Chemotherapy) may be delivered during cytoreductive surgery in selected patients. After visible deposits are removed, heated chemotherapy is circulated inside the abdominal cavity for a defined period to treat microscopic residual cancer cells. CRS-HIPEC is not appropriate for every type of peritoneal carcinomatosis. Its role differs according to the original cancer, available evidence and patient circumstances.

PIPAC (Pressurised Intraperitoneal Aerosol Chemotherapy) is a minimally invasive technique under investigation for selected specialist settings. When cancer cannot be removed safely, palliative and supportive care manages abdominal pain, ascites, nausea, bowel symptoms, nutrition, fatigue and emotional distress — focusing on quality of life alongside active treatment.

No. CRS-HIPEC is a major treatment option for carefully selected patients. The treating team considers: primary cancer type (evidence differs for ovarian, colorectal, appendiceal, gastric and other cancers); extent of peritoneal disease; small bowel involvement; disease outside the peritoneum; response to previous treatment; general fitness; and likelihood of complete cytoreduction. The final recommendation should come from a specialist team that regularly manages peritoneal surface malignancies.

In some patients, yes. Some patients with limited peritoneal disease may be considered for cytoreductive surgery, with or without HIPEC, as part of a strategy intended to achieve long-term disease control. Others may benefit more from systemic treatment, targeted therapy or immunotherapy. For patients with extensive disease, treatment may focus on controlling cancer growth, relieving symptoms and maintaining quality of life. It would be misleading to suggest that HIPEC or surgery can cure every patient — an individual assessment is essential.

India is an option for patients seeking specialist evaluation and cancer treatment. Indian surgical oncology groups have published consensus recommendations through INDEPSO-ISPSM, addressing patient selection, preoperative work-up, cytoreductive surgery, systemic chemotherapy and intraperitoneal treatment for peritoneal malignancies.

For patients travelling to India, the first objective should be to establish whether the proposed treatment is medically appropriate — not simply to arrange a surgical appointment.

There is no single price for treating peritoneal carcinomatosis. Costs depend on the primary cancer, disease extent, treatment approach and the hospital's facilities. A patient receiving systemic chemotherapy may have a very different budget from someone undergoing extensive cytoreductive surgery with HIPEC.

Recovery varies depending on the extent of surgery, general health and whether complications occur. After CRS-HIPEC, patients may require intensive care or high-dependency monitoring, pain management, intravenous fluids, nutritional support, monitoring of kidney function and blood counts, physiotherapy, wound care and gradual return to oral food. Some patients need several weeks to regain strength; complete recovery may take months.

Indian expert consensus has specifically addressed enhanced recovery after CRS with or without HIPEC, emphasising structured postoperative care and multidisciplinary support. International patients should not book a fixed return journey before the treating surgeon confirms fitness to travel.

Patients should ask the surgeon about the centre's experience, expected complications, ICU arrangements and the plan for managing emergencies. The potential benefits must be weighed against significant surgical and treatment-related risks.

Patients with peritoneal disease may experience reduced appetite, abdominal swelling, nausea, early fullness and weight loss. Major surgery and chemotherapy increase nutritional demands. A clinical dietitian can help assess nutritional status, plan adequate protein and calorie intake, manage nausea and appetite changes, adapt food texture after abdominal surgery and monitor hydration. There is no single diet that treats peritoneal carcinomatosis — dietary changes should be discussed with the treating oncology team.

Yes. Recurrence is possible even after extensive treatment. Likelihood depends on primary cancer type, tumour biology, extent of disease at diagnosis, completeness of cytoreduction and response to systemic treatment. The treating team will establish a surveillance plan. Patients returning home should receive a written follow-up plan and copies of operative, pathology and treatment records.

Patients from Tanzania, Kenya, Ethiopia, Uganda, Zambia, Nigeria, Iraq and other countries may consider India for specialist cancer assessment. It is particularly important to share medical records with the specialist team before making travel arrangements.

GAF Healthcare supports international patients coordinating medical treatment in India — including collecting and organising medical records, coordinating specialist consultations, requesting hospital opinions and estimates, appointment coordination, medical visa support, airport transfers, accommodation and interpreter arrangements. Clinical decisions remain with the treating doctors.

Medical Disclaimer: This article is intended for educational purposes only. It does not replace a consultation with a qualified oncologist or surgical oncologist. Treatment eligibility, prognosis and costs must be determined individually by the treating medical team.